PMID- 28837114 OWN - NLM STAT- MEDLINE DCOM- 20180503 LR - 20181113 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 18 IP - 9 DP - 2017 Aug 24 TI - Polydeoxyribonucleotide Ameliorates Lipopolysaccharide-Induced Lung Injury by Inhibiting Apoptotic Cell Death in Rats. LID - 10.3390/ijms18091847 [doi] LID - 1847 AB - Lung injury is characterized by diffuse lung inflammation, alveolar-capillary destruction, and alveolar flooding, resulting in respiratory failure. Polydexyribonucleotide (PDRN) has an anti-inflammatory effect, decreasing inflammatory cytokines, and suppressing apoptosis. Thus, we investigated its efficacy in the treatment of lung injury, which was induced in rats using lipopolysaccharide (LPS). Rats were randomly divided into three groups according to sacrifice time, and each group split into control, lung injury-induced, and lung injury-induced + PDRN-treated groups. Rats were sacrificed 24 h and 72 h after PDRN administration, according to each group. Lung injury was induced by intratracheal instillation of LPS (5 mg/kg) in 0.2 mL saline. Rats in PDRN-treated groups received a single intraperitoneal injection of 0.3 mL distilled water including PDRN (8 mg/kg), 1 h after lung injury induction. Percentages of terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)-positive, cleaved caspase-3-, -8-, and -9-positive cells, the ratio of Bcl-2-associated X protein (Bax) to B-cell lymphoma 2 (Bcl-2), and expressions of inflammatory cytokines (tumor necrosis factor-alpha, interleukin-6) were decreased by PDRN treatment in the LPS-induced lung injury rats. Therefore, treatment with PDRN reduced lung injury score. This anti-apoptotic effect of PDRN can be ascribed to the enhancing effect of PDRN on adenosine A(2A) receptor expression. Based on these results, PDRN might be considered as a new therapeutic agent for the treatment of lung injury. FAU - An, Jin AU - An J AD - Department of Pulmonary and Critical Care Medicine, Kyung Hee University Hospital at Gangdong, Seoul 05278, Korea. anjin7487@gmail.com. FAU - Park, So Hee AU - Park SH AD - Department of Pulmonary and Critical Care Medicine, Kyung Hee University Hospital at Gangdong, Seoul 05278, Korea. sojjang01@gmail.com. FAU - Ko, Il-Gyu AU - Ko IG AD - Department of Physiology, College of Medicine, Kyung Hee University, Seoul 02447, Korea. rhdlfrb@naver.com. FAU - Jin, Jun-Jang AU - Jin JJ AD - Department of Physiology, College of Medicine, Kyung Hee University, Seoul 02447, Korea. threej09@hanmail.net. FAU - Hwang, Lakkyong AU - Hwang L AD - Department of Physiology, College of Medicine, Kyung Hee University, Seoul 02447, Korea. LHWANGPHD@gmail.com. FAU - Ji, Eun-Sang AU - Ji ES AD - Department of Physiology, College of Medicine, Kyung Hee University, Seoul 02447, Korea. wldmstkd11@hanmail.net. FAU - Kim, Sang-Hoon AU - Kim SH AD - Department of Physiology, College of Medicine, Kyung Hee University, Seoul 02447, Korea. spdlvcjstkd@naver.com. FAU - Kim, Chang-Ju AU - Kim CJ AD - Department of Physiology, College of Medicine, Kyung Hee University, Seoul 02447, Korea. changju@khu.ac.kr. FAU - Park, So Young AU - Park SY AD - Department of Pulmonary and Critical Care Medicine, Kyung Hee University Medical Center, Seoul 05278, Korea. sy.park12@gmail.com. FAU - Hwang, Jae-Joon AU - Hwang JJ AD - Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul 05278, Korea. hjjoon00@naver.com. FAU - Choi, Cheon Woong AU - Choi CW AD - Department of Pulmonary and Critical Care Medicine, Kyung Hee University Hospital at Gangdong, Seoul 05278, Korea. ccwmdphd@gmail.com. LA - eng PT - Journal Article DEP - 20170824 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Cytokines) RN - 0 (Inflammation Mediators) RN - 0 (Lipopolysaccharides) RN - 0 (Polydeoxyribonucleotides) RN - 0 (Proto-Oncogene Proteins c-bcl-2) RN - 0 (Receptor, Adenosine A2A) RN - 0 (bcl-2-Associated X Protein) RN - EC 3.4.22.- (Caspase 3) RN - EC 3.4.22.- (Caspase 8) RN - EC 3.4.22.- (Caspase 9) SB - IM MH - Acute Lung Injury/drug therapy/*etiology/*metabolism/pathology MH - Animals MH - Apoptosis/*drug effects MH - Caspase 3/metabolism MH - Caspase 8/metabolism MH - Caspase 9/metabolism MH - Cytokines/metabolism MH - Disease Models, Animal MH - Gene Expression MH - Inflammation Mediators/metabolism MH - Lipopolysaccharides/*adverse effects MH - Lung/drug effects/metabolism/pathology MH - Male MH - Polydeoxyribonucleotides/*pharmacology MH - Proto-Oncogene Proteins c-bcl-2/genetics/metabolism MH - Rats MH - Receptor, Adenosine A2A/metabolism MH - bcl-2-Associated X Protein/genetics/metabolism PMC - PMC5618496 OTO - NOTNLM OT - adenosine A2A receptor OT - apoptosis OT - lipopolysaccharide OT - lung injury OT - polydexyribonucleotide COIS- The authors declare no conflict of interest. EDAT- 2017/08/25 06:00 MHDA- 2018/05/04 06:00 PMCR- 2017/09/01 CRDT- 2017/08/25 06:00 PHST- 2017/06/29 00:00 [received] PHST- 2017/08/21 00:00 [revised] PHST- 2017/08/21 00:00 [accepted] PHST- 2017/08/25 06:00 [entrez] PHST- 2017/08/25 06:00 [pubmed] PHST- 2018/05/04 06:00 [medline] PHST- 2017/09/01 00:00 [pmc-release] AID - ijms18091847 [pii] AID - ijms-18-01847 [pii] AID - 10.3390/ijms18091847 [doi] PST - epublish SO - Int J Mol Sci. 2017 Aug 24;18(9):1847. doi: 10.3390/ijms18091847.